Filing Flows

Filing Flows › Companies › Onconetix › Cash flow

Onconetix cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$1.9M in Q2 2026 · −$10.3M over twelve months

Operating cash flow−$1.9M
Free cash flow−$1.9M
Cash conversion cycle-10633 days

Analysis

In Q2 2026, Onconetix generated −$1.9M of operating cash flow. That is $508K less than in Q2 2025 (−$1.4M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$10.3M; the largest uses were operating cash flow ($10.3M), net borrowing (+) / repaid (−) ($4.6M); besides operations, cash came from other financing ($15.9M), shares issued ($4.3M); the cash balance rose by $5.7M.

Operating cash flow was −$1.9M against net income of −$2.9M. The largest differences: impairments +$486K, payables +$312K, inventory −$76K.

Its cash conversion cycle was -10633 days (receivables 122 + inventory 1236 − payables 11991): suppliers fund its working capital.

Free cash flow

Onconetix: free cash flow by quarterOnconetix: free cash flow by quarter−$1.1MQ3 2024−$922KQ4 2024−$2.0MQ1 2025−$1.4MQ2 2025−$3.2MQ3 2025−$3.1MQ4 2025−$2.1MQ1 2026−$1.9MQ2 2026
Operating cash flow less capital spending.
Onconetix: operating cash flow against capital spendingOnconetix: operating cash flow against capital spendingOperating cash flowCapital spending−$1.1M$2KQ3 2024−$918K$4KQ4 2024−$2.0M$0Q1 2025−$1.4M$0Q2 2025−$3.2M$0Q3 2025−$3.1M$0Q4 2025−$2.1M$0Q1 2026−$1.9M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$1.9M, Capital spending $0.

Capital allocation, year by year

Onconetix: where the cash came from (up) and went (down), by fiscal yearOnconetix: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow −$2.0MFY2021: Capital spending −$2KFY2021FY2022: Operating cash flow −$8.7MFY2022: Net borrowing $33.1MFY2022: Shares issued $36.8MFY2022: Capital spending −$80KFY2022: Buybacks −$567K$69.9MFY2022FY2023: Operating cash flow −$13.6MFY2023: Net borrowing −$1.2MFY2023: Shares issued $2.3MFY2023: Capital spending −$80KFY2023: Acquisitions $1.1M$3.4MFY2023FY2024: Operating cash flow −$10.5MFY2024: Net borrowing −$1.3MFY2024: Shares issued $1.6MFY2024: Capital spending −$28K$1.6MFY2024FY2025: Operating cash flow −$9.7MFY2025: Net borrowing −$5.8MFY2025: Shares issued $6.4M$6.4MFY2025
Over these 5 years operating cash flow totalled −$44.5M; the largest uses were operating cash flow ($44.5M) and net borrowing ($8.3M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$5.9M
Debtnone
Net cash$5.9M
Cash runway7 months

Onconetix is burning cash: its operations consume cash, a free cash flow of −$10.3M a year at the current rate against $5.9M of cash and investments: a runway of about 7 months before any new financing.

Where the cash came from and went

Onconetix: sources (+) and uses (−) of cash, Q2 2026Onconetix: sources (+) and uses (−) of cash, Q2 2026Other financing$4.2MCash drawn (+) / kept (−)−$2.2MOperating cash flow−$1.9MExchange rates−$24K
Onconetix: sources (+) and uses (−) of cash, TTM to Q2 2026Onconetix: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$15.9MOperating cash flow−$10.3MCash drawn (+) / kept (−)−$5.7MNet borrowing (+) / repaid (−)−$4.6MShares issued$4.3MExchange rates$329K

From profit to cash

Onconetix: net income to operating cash flow, Q2 2026Onconetix: net income to operating cash flow, Q2 2026Net income−$2.9MDepreciation & amortization$3KStock-based pay$7KImpairments$486KReceivables$41KInventory−$76KPayables$312KAccrued liabilities−$29KPrepaid and other assets$68KOperating cash flow−$1.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 2026122123611991-10633
Q1 20267145606407-5133
Q4 2025452482930-2637
Q3 202524035804-5399
Q2 2025123906528-6125
Q1 2025191775137-4941
Q4 202481646987-6815
Q3 202430431111-1038

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$1.9M———−$2.2M−$1.9M
Q1 2026−$2.1M—$247K—$1.5M−$2.1M
Q4 2025−$3.1M—$297K$21−$4.4M−$3.1M
Q3 2025−$3.2M—−$5.0M−$21−$553K−$3.2M
Q2 2025−$1.4M—−$225K$1.4M$1.3M−$1.4M
Q1 2025−$2.0M—−$838K$5.0M−$931K−$2.0M
Q4 2024−$918K−$4K−$403K—−$305K−$922K
Q3 2024−$1.1M−$2K−$350K—$589K−$1.1M

Onconetix: income statement and cash flow

Onconetix, Q2 2026: revenue $17K (-84% year over year). The chart follows the revenue to costs, profit and cash.

Onconetix: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.